10 molecular testing shifts defining oncology outcomes in 2026 The dawn of 2026 marks a transformative period for precision oncology as global health systems transition toward mandatory genomic profiling for early-stage malignancies. Under the latest WHO-aligned diagnostic frameworks, clinicians are no longer viewing biomarkers as optional data points but as the foundational architecture for...